Abstract: Ｏｂｊｅｃｔｉｖｅ：To observe the efficacy of Roxadustat instead of recombinant human erythropoietin (rHuEPO) in treatment of anemia in patients with maintenance hemodialysis (MHD).
Ｍｅｔｈｏｄｏｌｏｇｙ：Seventythree MHD patients with rHuEPO dosage of 13 8056±5 2439 IU／week were collected from December 2019 to October 2020 in the department of blood purification of the First Affiliated Hospital of Xi′an Jiaotong University to assess hemoglobin (Hb), ferritin, Ca, Pi, PTH, CRP, and blood pressure levels before and after switching to Roxadustat.
Ｒｅｓｕｌｔｓ：Seventythree patients were treated with Roxadustat for at least one month, age 517±144 years, of whom 562％ were male; dialysis age 449±357 months; dry weight 613±154 kg. Baseline Hb 833±167 g／L; oral starting dosage of Roxadustat 1123±117 mg／dose, 3 times／week. The mean increases in Hb levels after 2, 4, 8, 12, 16, 24 and 32 weeks of Roxadustat treatment were 37±141 g／L, 89±179 g／L, 144±164 g／L, 186±03 g／L, 212±171 g／L and 288±161 g／L. The mean Hb was 109±104 g／L after 32 weeks at a dose of 929±159 mg／dose orally, 3 times／week. There were no statistical differences in ferritin, calcium, PTH, systolic on diastolic blood pressure from 2 weeks after Roxadustat treatment to 32 weeks after treatment compared to pretreatment.
Ｃｏｎｃｌｕｓｉｏｎ：This study found an increase in Hb after switching to Roxadustat in MHD patients whose Hb remained substandard despite treatment with high dose of rHuEPO for nephrogenic anaemia, without raising blood pressure.

Key words: Roxadustat,erythropoietin,maintenance dialysis patients,renal anemia